

duphalac[®] in lactulose liver failure

Duphalac (lactulose) is now well established as a valuable agent in the treatment of portal-systemic encephalopathy. A recent review in Gut describes its role in these terms.*

"Lactulose is a useful addition to the existing treatment of cirrhotic patients with neuropsychiatric disorders. Most patients respond particularly those with mild and relatively stable symptoms; such patients may receive lactulose indefinitely, and enjoy improved tolerance of dietary protein . . .
. . . lactulose is free from significant side effects, and therefore falls into place as a valuable alternative to antibiotics when prolonged therapy is required". *Gut, 1970, 11: 1043-1048

The following work on Duphalac in portal systemic encephalopathy has been published:

Treatment of chronic portal-systemic encephalopathy with lactulose *Lancet*, 1966, 1: 890-892

Portal-systemic encephalopathy treated with lactulose (letter) *Lancet*, 1966, 2: 281

Treatment of hepatic system encephalopathy with lactulose *Medical Journal of Australia*, 1968, 2: 160-163

Treatment of portacaval encephalopathy by lactulose *Presse medicale*, 1968, 76: 1675-1676

Cirrhosis, hyperammonaemia and lactulose *Tijdschrift voor Gastro-Enterologie*, 1968, 11: 123-139

Lactulose in the treatment of chronic portal-systemic encephalopathy: a double-blind clinical trial *New England Journal of Medicine*, 1969, 281: 408-412

Long-term treatment of portal-systemic encephalopathy with lactulose *Australasian Annals of Medicine*, 1969, 18: 117-123

Die Behandlungen des chronischen Coma hepaticum mit Laktulose

Therapeutische Umschau und medizinische Bibliographie, 1969, 26: 275-277

Lactulose treatment of chronic hepatportal encephalopathy: a clinical and electroencephalographic study

Acta medica Scandinavica, 1970, 187: 337-346

The value of EEG frequency analysis in hepatic encephalopathy *J. Ryl. Coll. Surg. Edinb.*, 1970, 15: 151-157

Some observations on the effects of treatment with lactulose on patients with chronic hepatic encephalopathy *Quarterly Journal of Medicine*, 1970, 39: 245-263

A controlled clinical trial of lactulose in hepatic encephalopathy *Gastroenterology*, 1970, 59: 827-832

Duphalac syrup is supplied in bottles of 200 ml and 2 litres. It contains lactulose 50% w/w, galactose 8% w/w and lactose 5% w/w.

Further information available on request.

The single solution

for parenteral nutrition



Aminoplex 5

1 litre three times per day provides 15g. of utilisable nitrogen and 3000K calories; the nutrient content being derived from synthetic L-Form amino acids, sorbitol and alcohol.

Geistlich Chester



*In co-operation with Salvia-Werk
G.m.b.H., Homburg/Saar, W. Germany.*

Medical literature
available from:
Geistlich Sons Ltd.,
Newton Bank,
Long Lane,
Chester CH2 3QZ.
Telephone
Chester 47534-7



GASTRIC REFLUX

GAVISCON REFLUX



causes heartburn

prevents heartburn


Reflux of gastric acid, which inflames and eventually erodes the delicate oesophageal mucosa, frequently gives rise to burning chest pain—described by the patient as 'heartburn'—a symptom which heralds more serious trouble unless it is dealt with promptly and thoroughly.

1 By forming a viscous demulcent gel which floats as a 'raft' over the stomach contents Gaviscon physically suppresses gastric reflux.

2 When reflux becomes particularly vigorous the Gaviscon 'raft' itself is the first fraction to enter the oesophagus where it presents a unique physical barrier to acid attack—even when the patient stoops or lies down.

3 By thus soothing and protecting the delicate mucosa Gaviscon prevents pain, permits regression of inflammation and allows the irritated cardiac 'sphincter' to resume its normal competence.

4 A double-blind trial in patients with sliding hiatus hernia showed that Gaviscon produced almost total relief of regurgitation and heartburn in 79% and 67% of the patients respectively.*



Heartburn in:
 Gastric reflux
 Reflux oesophagitis
 Hiatus hernia
 Pregnancy

GAVISCON^{Regd.}

GASTRIC REFLUX SUPPRESSANT

Gaviscon contains: Alginic Acid BPC, Sodium Alginate BPC, Magnesium Trisilicate BP, Dried Aluminium Hydroxide Gel BP, Sodium Bicarbonate BP, Sucrose BP and Mannitol BP. Gaviscon is available as mint flavoured tablets and chocolate flavoured granules.
 * *Current Medical Research and Opinion*, (1972) 1, 63.

CAVED-S TABLETS

SOME TRIAL SUMMARIES

GUT 1968-9 48-51

SUMMARY

In a double blind clinical trial in which 54 patients* were included, the effect of deglycyrrhizinized liquorice was investigated. Duodenal ulcer cases showed marked symptomatic improvement, with radiological healing demonstrable in a few cases.

*48 Duodenal ulcer patients: 6 gastric ulcer patients.

Further confirmation of the activity of the drug was obtained from the treatment of six cases of gastric ulcer all of which showed extensive healing. Radiology demonstrated that the effect of the drug was spasmolytic in all duodenal ulcer patients, and that the side-effects were minimal. The great advantage of the treatment is that patients can be treated as ambulant and with a minimum loss of work.

GUT 1971-72 449-451

SUMMARY

In our study no significant differences were found between the placebo and the treated groups.

The differences between the reported results are not easy to explain. Crossover trials in patients with duodenal ulcer are not easy to evaluate. In particular, it is not clear how after one month of reportedly successful therapy with complete relief of symptoms another drug (placebo) can be evaluated using clinical criteria. Even if the placebo is used first, the attack may be expected to subside within a month in part of the group.

In view of the conflicting reports more studies will have to be performed before a therapeutic effect can be attributed to deglycyrrhizinized liquorice in patients with duodenal ulcer.

It is not clear whether our results reflect on the efficacy of liquorice extract after the removal of carbenoxolone or merely on its efficacy in duodenal as contrasted to gastric ulcer. In common with others we found no side effects attributable to treatment with deglycyrrhizinized liquorice.

GUT 10 299-302 1969

SUMMARY

In a double-blind clinical trial of deglycyrrhizinized liquorice 16 patients with gastric ulcer received the active drug for four weeks in a dose of 760 mg thrice daily and 17 the placebo. All patients, except four from each group who remained ambulant, were treated as outpatients. The results of the trial were assessed by the change in the size of the ulcer crater on barium meal before and after treatment.

Of the patients given the active drug, on average the size of the ulcer niche was reduced by 78%; in six patients (44%) the crater disappeared radiologically. In contrast the average reduction in size of the ulcer niche of the placebo group was 34% and in only one (6%) did the ulcer disappear. The difference in the reduction in ulcer size in favour of the treated group compared with the control group is statistically significant ($P < 0.001$). None of the patients developed oedema and there was no excessive weight gain.


A pilot trial using Caved-(S) in a dose containing 760 mg of deglycyrrhizinized liquorice thrice daily for one month showed no toxic effects on fluid and electrolyte balance in 10 patients.

Protective Action of Deglycyrrhizinized Liquorice on the Occurrence of Stomach Ulcers in Pylorus-Ligated Rats. *Scand. J. Gastroent.*, 6, 683-686.

The effect of graded doses of a deglycyrrhizinized liquorice extract (d.Li.) was studied on the frequency of stomach ulcers and the secretion of gastric juice in pylorus-ligated rats. 25-50 mg of d.Li. given intraperitoneally reduced considerably the number of ulcers in comparison with the control group of rats without any significant changes in gastric secretion. Higher doses—100-200 mg—gave complete protection against the development of gastric ulcers and also reduced the output of gastric juice. The results give strong support for the existence of an ulcer-protecting principle in the d.Li.

Key-words: Gastric secretion; gastric ulcers; liquorice; pylorus-ligated rats.

Dept. of Pharmacology, Karolinska institutet, S-104 01 Stockholm 60, Sweden.



Where does an endoscopist look for all round service?

To KeyMed! The Company that boasts the most comprehensive fund of expertise in fiberoptic endoscopy.

To KeyMed! Selling and servicing Olympus instruments. Olympus, world leaders in fiberoptic endoscopes—cover more specialities than any other with the finest instruments.

KeyMed, the first Company with a comprehensive repair service by specially trained technicians, in new laboratories. KeyMed—the Company that takes the trouble to know what's going on in fiberoptic endoscopy around the world. And backs up its experience and knowledge with service second to none.

KEY MED
the specialist service for endoscopy equipment


KEY MED
specialised medical equipment limited

KeyMed House Stock Road
Southend on Sea SS2 5QH
Further information can be simply obtained by using the KEYMED Free Post Information Service, addressing envelope without postage to: KeyMed
Free Post Southend-on-Sea SS2 4BR.



Do you have a teaching problem?

*Why not consult
us with regard
to adapting your
existing instruments?*



THE MEDICAL SUPPLY ASSOCIATION LIMITED

KINGS CROSS ROAD, DUNDEE, DD2 3QE
BOURNE ROAD, BEXLEY, KENT, DA5 1LF


TELEPHONE 0382 88241
TELEPHONE CRAYFORD 29114

NEW ... for hospital use


the oral
alternative to
parenteral feeding

The first oral diet that *

*



inside
every Baritop can
are fine radiographs
waiting
to get out



The excellent fluidity and optimum concentration of Baritop 100 form a unique combination of properties which results in superior visualisation of mucosal detail. Carbon dioxide is incorporated as an effervescent agent to aid double-contrast procedures and enhance the exceptional palatability of the suspension.

Baritop 100 is the modern liquid barium specifically formulated to match the sophistication of present day equipment and techniques.

The elegant barium suspension at 100% w/v in convenient 300ml cans.

Low viscosity
High density
Carbonated
barium
Baritop 100

**world's finest micronised
barium suspension
from Japan**

Further information available
on request from

 **Concept Pharmaceuticals Limited**
Rickmansworth WD3 1EZ

Baritop is a registered trade mark

she gets them
to school
late...



because of
persistent
diarrhoea

Persistent diarrhoea is one of the commonest presenting symptoms of irritable colon—and it is quickly and easily controlled by Colofac. Colofac reduces colonic hyperactivity by a direct action exerted on the colon musculature. There are no atropine-like side effects or contra-indications. Colofac is supplied as tablets of 100 mg. mebeverine hydrochloride. Full information is available on request.

duphar DUPHAR LABORATORIES LIMITED WEST END SOUTHAMPTON TEL 04218 2281
PHILIP'S DUPHAR (IRELAND) LIMITED RAINSFORD STREET DUBLIN 8 TEL DUBLIN 754271 

colofac[®]
mebeverine

controls the colon
controls the diarrhoea

There's only one healing agent for peptic ulcers as well documented as Biogastrone



and that's Duogastrone

Carbenoxolone is the most thoroughly investigated healing agent available today—and interesting evidence is still mounting. For instance, a recent report* suggests very strongly that carbenoxolone's proven healing properties are not only due to an increase in protective mucus or the creation of a more favourable healing environment – but also to more radical influences. These investigations appear to demonstrate that carbenoxolone actually prolongs the life-span of mucosal epithelial cells and reduces the rate of cell turnover.

Fascinating findings which shed new light on the disease process and provoke re-appraisal of current therapies. *Gut, 1971, 12, 599-603

BIOGASTRONE®

Carbenoxolone sodium tablets for gastric ulcer.

DUOGASTRONE®

Carbenoxolone sodium capsules for duodenal ulcer.



Berk Pharmaceuticals Limited
Godalming & Shalford, Surrey.




The Queen's Award to Industry 1972 to Biorex Laboratories Limited for Technological Innovation in the Development and Production of the drug Carbenoxolone Sodium for the treatment of ulcers.

Made under licence from Biorex Laboratories London
British Patent numbers 843133, 1093286.

•Registered trade mark

J4273



Flatulent dyspepsia. A repeated problem.

The flatulent dyspeptic patient you see in hospital probably has a history of repeat visits to his general practitioner, and unsatisfactory responses to a variety of treatments.

After investigation you may feel he needs another change of treatment. But this time prescribe Maxolon. Maxolon prevents symptoms in 4 out of 5 patients, and within a month may resolve the probable underlying cause of the symptoms by stabilising disturbed gastro-duodenal motility.

Clinical experience with Maxolon is already showing that flatulent dyspepsia need no longer be a repeated problem.

Full information on the uses of Maxolon in hospital is available on request.

Maxolon* (metoclopramide) is a product of



**Beecham Research
Laboratories,**
Brentford, England



Maxolon for flatulent dyspepsia.

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Volume 8, No. 2, 1973

CONTENTS

Review: H. Schjónsby: <i>The Mechanism of Vitamin B₁₂ Malabsorption in Blind-Loop Syndrome</i> ..	97
F. Stadil & J. F. Rehfeld: <i>Determination of Gastrin in Serum. An Evaluation of the Reliability of a Radioimmunoassay</i> ..	101
Catja Johansson & F. Bårány: <i>A Retrospective Study on the Outcome of Massive Bleeding from Peptic Ulceration</i> ..	113
A. Berstad, H. Petersen, M. Roland & I. Liavåg: <i>Effect of Secretin on Pentagastrin-Stimulated Gastric Acid and Pepsin Secretion after Vagotomy in Man</i> ..	119
O. Kronborg: <i>A Follow-up of Patients Operated Upon for Recurrence after Vagotomy and Drainage for Duodenal Ulcer</i> ..	123
K. Ohlsson & H. Tegner: <i>Experimental Pancreatitis in the Dog. Demonstration of Trypsin in Ascitic Fluid, Lymph and Plasma</i> ..	129
I. Talstad, K. Rootwelt & E. Gjone: <i>Thrombocytosis in Ulcerative Colitis and Crohn's Disease</i> ..	135
I. Rahbek, J. Lintrup, E. Jensen & N. Kromann: <i>Beta-Glucuronidase Activity in Gastric Juice in Various Gastric Diseases</i> ..	139
E. Schruppf, H. Petersen, A. Berstad, J. Myren & B. Rosenlund: <i>The Effect of Secretin on Plasma Gastrin in the Zollinger-Ellison Syndrome</i> ..	145
P. Danö, J. Olsen & R. Vejlsgaard: <i>Giardia Intestinalis. A Prospective Investigation of the Prevalence in Denmark</i> ..	151
S. Ritland, J. P. Blomhoff, K. Elgjo & E. Gjone: <i>Lipoprotein-X (LP-X) in Liver Disease</i> ..	155
Vibeke Binder, O. Bonnevie, T.Cl. Gertz, P. A. Krasilnikoff, S. Vestermark & P. Riis: <i>Ulcerative Colitis in Children. Treatment, Course, and Prognosis</i> ..	161
J. Rask-Madsen & P. Brix Jensen: <i>Electrolyte Transport Capacity and Electrical Potentials of the Normal and the Inflamed Human Rectum in Vivo</i> ..	169
G. Liedberg, K. C. Nielsen, Ch. Owman & N.-O. Sjöberg: <i>Adrenergic Contribution to the Abdominal Vagus Nerves in the Cat</i> ..	177
T. Stærh Johansen & H. Baden: <i>Re-appraisal of the Sengstaken-Blakemoore Ballon Tamponade for Bleeding Esophageal Varices: Results in 91 Patients</i> ..	181
B. Frenning: <i>The Effects of Large Osmolality Variations on the Gastric Mucosal Surface Ultrastructure</i> ..	185

Issued 20 March 1973

THE SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY publishes original papers in gastroenterology and pertinent fields of nutrition. Each issue contains about 100 pages; eight issues form one annual volume. Supplements are supplied free of charge to subscribers. The subscription price, including postage, is N. kr. 220.-(U.S. \$36.-) payable in advance.

Editorial Correspondence

Manuscripts should be addressed to the managing editor. The Scandinavian Journal of Gastroenterology has no objection to the reproduction of short passages and illustrations from this journal without further formality than acknowledgement of the source.

Business Communications

Business communications, including subscriptions and orders for reprints or advertisements, should be sent to the publishers.

Publishers
UNIVERSITETSFORLAGET
P.O. Box 307, Blindern, Oslo 3 Norway

EDIZIONI MINERVA MEDICA

Quarterly Index

**MINERVA MEDICO-
BIBLIOGRAFICA**

A list of the world's medical, surgical
and specialist literature.

Annual Subscription rate \$26.00

Italian Medical Journal in
English

PANMINERVA MEDICA

The Journal of the Italian Medical
Association Monthly Review of
Italian Medicine.

Annual subscription rate \$14.00

EUROPA MEDICOPHYSICA

Official Organ of the European Federation of Physical and Rehabilitation Medicine and of the
Italian Society of Physical and Rehabilitation Medicine. Quarterly publication.

Annual subscription price \$12.00

INTERNATIONAL MEDICAL JOURNAL IN ENGLISH

**THE JOURNAL OF
SPORTS MEDICINE AND
PHYSICAL FITNESS**

Official Journal of the 'Fédération
Internationale de Médecine Sportive'.
Quarterly publication.

Annual subscription rate \$14.00

**THE JOURNAL OF
CARDIOVASCULAR
SURGERY**

Official Journal of the International
Cardiovascular Society.
Bi-monthly publication.

Annual subscription rate \$18.00

EDIZIONI MINERVA MEDICA

corso Bramante 83-85 - 10126 Torino - Italy